Search Results

Filter
  • 1-10 of  50 results for ""Proprotein Convertases""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Proprotein convertases in health and disease.

  • Authors : Artenstein AW; Center for Biodefense and Emerging Pathogens, Department of Medicine, Memorial Hospital of Rhode Island, Pawtucket 02860, USA. ; Opal SM

Subjects: Proprotein Convertases/Proprotein Convertases/Proprotein Convertases/*physiology; Alzheimer Disease/Alzheimer Disease/Alzheimer Disease/enzymology ; Communicable Diseases/Communicable Diseases/Communicable Diseases/enzymology

  • Source: The New England journal of medicine [N Engl J Med] 2011 Dec 29; Vol. 365 (26), pp. 2507-18.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

PCSK9 Inhibition to Reduce Cardiovascular Events.

  • Authors : Dullaart RPF; From the Department of Endocrinology, University of Groningen, University Medical Center, Groningen, the Netherlands.

Subjects: Cholesterol, LDL* ; Proprotein Convertases*; Humans

  • Source: The New England journal of medicine [N Engl J Med] 2017 May 04; Vol. 376 (18), pp. 1790-1791. Date of Electronic Publication: 2017 Mar 17.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Cholesterol, LDL/Cholesterol, LDL/Cholesterol, LDL/*blood ; Hyperlipidemias/Hyperlipidemias/Hyperlipidemias/*drug therapy

  • Source: The New England journal of medicine [N Engl J Med] 2014 May 08; Vol. 370 (19), pp. 1809-19. Date of Electronic Publication: 2014 Mar 29.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

  • Authors : Stein EA; Metabolic and Atherosclerosis Research Center, 4685 Forest Ave., Cincinnati, OH 45212, USA. ; Mellis S

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*administration & dosage ; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*administration & dosage ; Cholesterol, LDL/Cholesterol, LDL/Cholesterol, LDL/*blood

  • Source: The New England journal of medicine [N Engl J Med] 2012 Mar 22; Vol. 366 (12), pp. 1108-18.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

  • Authors : Everett BM; From Harvard Medical School and Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital - both in Boston (B.M.E.); the Department of Medicine, Alpert Medical School, and the Department of Health Services, Policy, and Practice, School of Public Health, Brown University

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*therapeutic use ; Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*prevention & control

  • Source: The New England journal of medicine [N Engl J Med] 2015 Oct 22; Vol. 373 (17), pp. 1588-91. Date of Electronic Publication: 2015 Oct 07.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.

  • Authors : Schulman KA; From the Duke Clinical Research Institute (K.A.S., S.D.R.) and the Duke Institute for Health Innovation (S.B.), Duke Translational Medicine Institute, and the Department of Medicine (K.A.S., S.D.R.), Duke University School of Medicine, Durham, NC.; Balu S

Subjects: Drug Costs*; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*economics ; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*economics

  • Source: The New England journal of medicine [N Engl J Med] 2015 Oct 22; Vol. 373 (17), pp. 1591-3. Date of Electronic Publication: 2015 Oct 07.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium:

Record details

×
Editorial & Opinion

Evolocumab in hyperlipidemia.

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Cholesterol, LDL/Cholesterol, LDL/Cholesterol, LDL/*blood ; Hyperlipidemias/Hyperlipidemias/Hyperlipidemias/*drug therapy

  • Source: The New England journal of medicine [N Engl J Med] 2014 Aug 28; Vol. 371 (9), pp. 877-8.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

Evolocumab in hyperlipidemia.

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Cholesterol, LDL/Cholesterol, LDL/Cholesterol, LDL/*blood ; Hyperlipidemias/Hyperlipidemias/Hyperlipidemias/*drug therapy

  • Source: The New England journal of medicine [N Engl J Med] 2014 Aug 28; Vol. 371 (9), pp. 876.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

Evolocumab in hyperlipidemia.

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Cholesterol, LDL/Cholesterol, LDL/Cholesterol, LDL/*blood ; Hyperlipidemias/Hyperlipidemias/Hyperlipidemias/*drug therapy

  • Source: The New England journal of medicine [N Engl J Med] 2014 Aug 28; Vol. 371 (9), pp. 876-7.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Heptanoic Acids/Heptanoic Acids/Heptanoic Acids/*therapeutic use ; Hypercholesterolemia/Hypercholesterolemia/Hypercholesterolemia/*drug therapy

  • Source: The New England journal of medicine [N Engl J Med] 2012 Nov 15; Vol. 367 (20), pp. 1891-900. Date of Electronic Publication: 2012 Oct 31.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium:

Record details

×
  • 1-10 of  50 results for ""Proprotein Convertases""